

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of Rui Kang.



China Renji Medical Group Ltd
中國仁濟醫療集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 648)



**RUI KANG PHARMACEUTICAL GROUP
INVESTMENTS LIMITED**
銳康藥業集團投資有限公司
(Incorporated in the Cayman Islands and continued in
Bermuda with limited liability)
(Stock code: 8037)

**JOINT ANNOUNCEMENT:
COMPLETION OF SUBSCRIPTION
OF RUI KANG SHARES UNDER SPECIFIC MANDATE**

Reference is made to the joint announcement of Rui Kang Pharmaceutical Group Investments Limited (“**Rui Kang**”) and China Renji Medical Group Limited (“**China Renji**”) dated 14 November 2014 (the “**Joint Announcement**”), the circular of Rui Kang dated 24 December 2014 and the announcement of Rui Kang dated 16 January 2015. Unless otherwise stated, capitalised terms used in this joint announcement shall have the same meanings as those defined in the Joint Announcement.

The Rui Kang Board and the China Renji Board are pleased to announce that all the conditions precedent of the Subscription Agreement had been fulfilled and completion of the Subscription took place on 23 January 2015 whereby the 257,812,500 Subscription Shares were allotted and issued to China Renji at the Subscription Price of HK\$0.128 per Subscription Share. The 257,812,500 Subscription Shares represent approximately 20.41% of the issued share capital of Rui Kang as enlarged by the allotment and issue of the Subscription Shares.

The net price to Rui Kang of each Subscription Share is approximately HK\$0.127. The net proceeds are estimated to be HK\$32.7 million from the Subscription after deduction of expenses.

The following table sets out the shareholding structure of Rui Kang immediately before completion of the Subscription and immediately after completion of the Subscription:

	Immediately before completion of the Subscription		Immediately after completion of the Subscription	
	<i>No. of Shares</i>	<i>Approximate %</i>	<i>No. of Shares</i>	<i>Approximate %</i>
China Renji	–	–	257,812,500	20.41
Public Rui Kang Shareholders	1,005,624,000	100.00	1,005,624,000	79.59
Total	1,005,624,000	100.00	1,263,436,500	100.00

On behalf of the Board
China Renji Medical Group Limited
CHAN Ka Chung
Chairman

By order of the Board
**Rui Kang Pharmaceutical Group
Investments Limited**
LEUNG Pak Hou Anson
Executive Director

Hong Kong, 23 January 2015

As at the date of this joint announcement, the board of directors of China Renji comprises four executive directors, namely Mr. Chan Ka Chung, Dr. Hui Ka Chun, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and four independent non-executive directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen, Mr. Lam Chun Ho and Ms. Wu Yan.

As of the date of this joint announcement, the executive directors of Rui Kang are Mr. CHEUNG Hung (Chairman), Mr. LEUNG Pak Hou Anson and Ms. CHEN Miaoping (Chief Executive Officer); and the independent non-executive directors of Rui Kang are Mr. YUEN Chun Fai, Mr. LEUNG Ka Fai and Mr. HO Fung Shan Bob.

This joint announcement, for which the directors of Rui Kang collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to Rui Kang. The directors of Rui Kang, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this joint announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this joint announcement misleading.

This joint announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of Rui Kang at www.ruikang.com.hk.